RecruitingPhase 2NCT06511648
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Studying Muscular tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Spanish Oncology Genito-Urinary Group
- Intervention
- Erdafitinib monotherapy(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (23)
- CLCC Jean Perrin, Clermont-Ferrand, France
- CLCC Léon Bérard, Lyon, France
- Institut Mutualiste Montsouris, Paris, France
- IUCT, Toulouse, France
- Institut Gustave Roussy, Villejuif, France
- IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
- A.O. Ordine Mauriziano, Ospedale Umberto I, Turi, Italy
- Ospedale Molinette, Turin, Italy
- Hospital Clínic De Barcelona, Barcelona, Catalonia, Spain
- Hospital De Sabadell (Parc Taulí), Barcelona, Catalonia, Spain
- Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain
- Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain
- ICO l' Hospitalet, Barcelona, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital Universitario de Toledo, Toledo, Spain
- +8 more locations on ClinicalTrials.gov
Collaborators
Janssen-Cilag Ltd. · Pivotal S.L.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06511648 on ClinicalTrials.govOther trials for Muscular tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07144319Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyPhotocure
- RECRUITINGPHASE2NCT07475403Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07475806A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderAstellas Pharma Global Development, Inc.
- RECRUITINGNANCT07431788The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionErkan Gol
- RECRUITINGNANCT07339761Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyUniversity of Aarhus
- RECRUITINGPHASE2NCT07363057A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer SurvivorsGI Innovation, Inc.
- RECRUITINGPHASE3NCT06919965A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerJanssen Research & Development, LLC
- ACTIVE NOT RECRUITINGNANCT07001670Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection SurgeryIstanbul University